MiMedx Group (NASDAQ:MDXG – Get Free Report) is anticipated to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect MiMedx Group to post earnings of $0.07 per share and revenue of $89.42 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
MiMedx Group Stock Down 2.1 %
MDXG opened at $8.22 on Wednesday. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The business has a 50-day moving average of $8.92 and a 200-day moving average of $7.62. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market capitalization of $1.21 billion, a PE ratio of 14.95 and a beta of 1.94.
Analyst Ratings Changes
Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, MiMedx Group has an average rating of “Buy” and an average price target of $12.00.
MiMedx Group Company Profile
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
Read More
- Five stocks we like better than MiMedx Group
- Retail Stocks Investing, Explained
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- 3 Monster Growth Stocks to Buy Now
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.